These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36622668)

  • 1. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
    J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of severe nivolumab-induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma.
    Mueller KA; Cordisco MR; Scott GA; Plovanich ME
    Pediatr Dermatol; 2023 Jan; 40(1):154-156. PubMed ID: 35882548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
    J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
    Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
    Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.
    Shah RR; Bhate C; Hernandez A; Ho CH
    Dermatol Ther; 2022 May; 35(5):e15432. PubMed ID: 35266258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
    Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
    Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
    Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
    J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
    Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
    Storgard R; Markova A
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K; Masuzawa M; Amoh Y
    J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.